Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Summary

This trial aims to compare the benefits and risks of tisagenlecleucel to blinatumomab or inotuzumab in adult patients with relapsed or refractory ALL. This trial investigates tisagenlecleucel as an additional treatment option for this patient population with high unmet medical need.

Timeline

Start

2020-06-05

Primary completion

2025-10-08

Completion

2026-01-07

Outcome

Outcome not reported

Stopped: “Novartis is no longer pursuing this study because of planned investigation of novel CAR-T therapies in this patient population.”

Drugs

Indications